Data from Pharmawand - Curated by EPG Health - Date added 07 August 2017

The National Institute for Health and Care Excellence (NICE) issued draft guidance recommending against Tecentriq (atezolizumab) from Roche for treating locally advanced or metastatic urothelial carcinoma in adults after prior platinum-containing chemotherapy. However, the agency asked the company to submit a proposal for inclusion of the drug in the Cancer Drugs Fund (CDF for patients whose cancer has not yet been treated and who cannot have cisplatin-based chemotherapy.

NICE noted that despite clinical data backing the efficacy of Tecentriq, the treatment has not been directly compared with other therapies. The regulator stated that while the therapy met its criteria for being considered a life-prolonging drug, the lack of data examining the drug relative to competing treatments makes the benefit uncertain.

Comment: The EU CHMP has adopted a positive opinion for the use of Tecentriq (atezolizumab) as a monotherapy for the treatment of adults with locally advanced or metastatic urothelial carcinoma (mUC) who have been previously treated with a platinum based chemotherapy or who are considered ineligible for cisplatin chemotherapy.


You will need to login, to leave a comment. is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Fluid Management

Fluid Management

Are you up-to-date with the latest evidence of effective procedures for fluid management?

+ 2 more

CDK 4/6 inhibitors in metastatic breast cancer

CDK 4/6 inhibitors in metastatic breast cancer

The CDK 4/6 Inhibitors in Metastatic Breast Cancer Learning Zone provides insights and information for metastatic breast cancer (mBC) and CDK 4/6 signalling. This includes the burden and pathophysiology of the disease, the role of CDK 4/6 in cell proliferation and an overview of the CDK 4/6 inhibitors that have been approved for the management of mBC.

Load more

Related Content